Huadong Medicine Buys Acute Ischemic Stroke Drug's Rights for 1.19 Billion Yuan

MT Newswires Live07-15

Huadong Medicine (SHE:000963), through unit Hangzhou Sino-US Huadong Pharmaceutical, bought the market rights for TTYP01 tablets from Suzhou Aozhong Biotechnology for 1.19 billion yuan, according to a Monday filing on the Shenzhen Stock Exchange.

The fee includes development, regulatory and sales milestone payments. The company will pay a down payment of 100 million yuan.

The Chinese pharmaceutical company will manufacture and sell the drug in China, Hong Kong, Macau and Taiwan.

The drug for acute ischemic stroke already completed the phase III clinical studies and is expected to be submitted for marketing in the fourth quarter of the year.

Price (RMB): Â¥27.67, Change: Â¥-0.05, Percent Change: -0.18%

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2451761682?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-07-15 16:59","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2451761682","market":"fut","top_or_hot":-1,"title":"Huadong Medicine Buys Acute Ischemic Stroke Drug's Rights for 1.19 Billion Yuan","media":"MT Newswires Live","content":"<html><body><p> Huadong Medicine (SHE:000963), through unit Hangzhou Sino-US Huadong Pharmaceutical, bought the market rights for TTYP01 tablets from Suzhou Aozhong Biotechnology for 1.19 billion yuan, according to a Monday filing on the Shenzhen Stock Exchange.</p><p>The fee includes development, regulatory and sales milestone payments. The company will pay a down payment of 100 million yuan.</p><p>The Chinese pharmaceutical company will manufacture and sell the drug in China, Hong Kong, Macau and Taiwan.</p><p>The drug for acute ischemic stroke already completed the phase III clinical studies and is expected to be submitted for marketing in the fourth quarter of the year.</p><p>Price (RMB): Â¥27.67, Change: Â¥-0.05, Percent Change: -0.18%</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Huadong Medicine Buys Acute Ischemic Stroke Drug's Rights for 1.19 Billion Yuan</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHuadong Medicine Buys Acute Ischemic Stroke Drug's Rights for 1.19 Billion Yuan\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-07-15 16:59 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Huadong Medicine (SHE:000963), through unit Hangzhou Sino-US Huadong Pharmaceutical, bought the market rights for TTYP01 tablets from Suzhou Aozhong Biotechnology for 1.19 billion yuan, according to a...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1969619763.USD","symbol_name":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2451761682","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2451761682","pubTimestamp":1721033954,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Huadong Medicine , through unit Hangzhou Sino-US Huadong Pharmaceutical, bought the market rights for TTYP01 tablets from Suzhou Aozhong Biotechnology for 1.19 billion yuan, according to a Monday filing on the Shenzhen Stock Exchange.The fee includes development, regulatory and sales milestone payments. The company will pay a down payment of 100 million yuan.The Chinese pharmaceutical company will manufacture and sell the drug in China, Hong Kong, Macau and Taiwan.The drug for acute ischemic stroke already completed the phase III clinical studies and is expected to be submitted for marketing in the fourth quarter of the year.Price : 27.67, Change: -0.05, Percent Change: -0.18%","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","BK0175":"白马股","000963":"华东医药","BK0132":"高送转概念","BK0188":"融资融券","BK0183":"MSCI概念","BK0187":"一线龙头","BK0209":"零售","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","BK0196":"行业龙头"},"translate_title":"华东医药11.9亿元购急性缺血性脑卒中药物权益","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"000963":0.9},"content_text":"Huadong Medicine (SHE:000963), through unit Hangzhou Sino-US Huadong Pharmaceutical, bought the market rights for TTYP01 tablets from Suzhou Aozhong Biotechnology for 1.19 billion yuan, according to a Monday filing on the Shenzhen Stock Exchange.The fee includes development, regulatory and sales milestone payments. The company will pay a down payment of 100 million yuan.The Chinese pharmaceutical company will manufacture and sell the drug in China, Hong Kong, Macau and Taiwan.The drug for acute ischemic stroke already completed the phase III clinical studies and is expected to be submitted for marketing in the fourth quarter of the year.Price (RMB): Â¥27.67, Change: Â¥-0.05, Percent Change: -0.18%","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.28.3","shortVersion":"4.28.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2451761682"}